How to Get Rid of PCOS Belly Fat

How to get rid of PCOS belly fat is one of the most common questions asked by people living with polycystic ovary syndrome. The accumulation of abdominal fat in PCOS is not simply a matter of diet or willpower; it is driven by insulin resistance, androgen excess, and chronic low-grade inflammation, all of which are core features of the condition. Understanding these mechanisms is essential for choosing strategies that actually work. This article explains why PCOS causes belly fat to build up, and outlines evidence-based dietary, exercise, and medical approaches supported by NHS, NICE, and international PCOS guidelines.

Why does PCOS cause belly fat to build up?

PCOS causes belly fat to accumulate primarily through insulin resistance, which drives excess fat storage in the abdominal region, compounded by elevated androgens and chronic low-grade inflammation that further disrupt fat metabolism.

Polycystic ovary syndrome (PCOS) can cause belly fat to accumulate partly because of insulin resistance, a feature of the condition in which the body's cells respond poorly to insulin, prompting the pancreas to produce more of it. Elevated insulin levels can encourage the body to store excess energy as fat, and this storage tends to concentrate in the abdominal region. This pattern is sometimes called central or visceral adiposity, and it differs from subcutaneous fat because it sits deeper around the internal organs, where it is metabolically active and can be difficult to reduce.

Hormonal imbalances compound the problem. People with PCOS typically have higher levels of androgens (male-type hormones such as testosterone), and research has linked elevated androgens to preferential fat deposition around the abdomen. Chronic low-grade inflammation, which is also common in PCOS, can further disrupt fat metabolism and make weight management more challenging. The NHS and NICE Clinical Knowledge Summary (CKS) on PCOS both recognise insulin resistance and androgen excess as central features of the condition.^[1][19]

It is important to understand that not everyone with PCOS is overweight, and abdominal fat can be a concern even in those with a body mass index (BMI) in the normal range. Waist circumference is a useful additional marker of metabolic risk in PCOS. Recognising the specific mechanisms at play is the first step towards choosing strategies that address the underlying causes rather than simply restricting food intake.

What diet changes actually help with PCOS belly fat?

A low-GI, Mediterranean-style diet prioritising wholegrains, lean protein, and healthy fats is the most evidence-supported dietary approach, as it directly targets insulin resistance, the key driver of PCOS belly fat.

A low-glycaemic index (GI) diet is a well-studied dietary approach for reducing PCOS-related belly fat, because it targets insulin resistance by slowing the absorption of glucose into the bloodstream. Foods with a low GI include oats, legumes, most vegetables, berries, and wholegrains, while high-GI foods such as white bread, sugary drinks, and processed snacks cause rapid blood sugar spikes that can worsen insulin resistance over time. NICE CKS on PCOS and the 2023 International Evidence-Based Guideline for PCOS (ESHRE/ASRM) both support lifestyle modification, including dietary change, as a first-line intervention.^[11]

Protein intake also matters. Including adequate protein at each meal, from sources such as eggs, fish, chicken, tofu, or pulses, helps to stabilise blood sugar, reduce hunger hormones, and preserve lean muscle mass during weight loss. Healthy fats from oily fish, avocado, nuts, and olive oil support anti-inflammatory pathways. A Mediterranean-style eating pattern, which combines low-GI carbohydrates, lean protein, and healthy fats, is supported by evidence in PCOS and tends to be sustainable long term.

Reducing ultra-processed foods and added sugars is consistently recommended across dietary guidelines, and for people with PCOS this is particularly relevant given the link between sugar consumption and worsening insulin resistance. The NHS Eatwell Guide provides a practical framework for balanced eating that is broadly consistent with these principles.

• Prioritise: wholegrains, vegetables, legumes, lean protein, oily fish

• Limit: white refined carbohydrates, sugary drinks, ultra-processed snacks

• Consider: eating regular meals to avoid blood sugar dips that trigger cravings

A registered dietitian with experience in PCOS can provide personalised guidance. A GP referral may be available through the NHS, though access to NHS dietetic services varies by local Integrated Care Board (ICB). The British Dietetic Association (BDA) PCOS Food Fact Sheet is a useful UK-specific resource.

Does exercise help reduce abdominal fat with PCOS?

Yes, both aerobic exercise and resistance training reduce visceral fat and improve insulin sensitivity in PCOS; UK guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week as a starting point.

Regular physical activity does help reduce abdominal fat in people with PCOS, and its benefits extend beyond calorie expenditure to directly improving insulin sensitivity, which addresses one of the key drivers of central weight gain. A systematic review published in Human Reproduction Update found that both aerobic exercise and resistance training improved metabolic and hormonal markers in women with PCOS, with reductions in waist circumference and fasting insulin among the most consistent findings.

Aerobic exercise, such as brisk walking, cycling, swimming, or jogging, is effective at reducing visceral fat when performed consistently. The UK Chief Medical Officers' Physical Activity Guidelines, reflected in NHS guidance, recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, and this is a reasonable starting point for people with PCOS.^[9][10] High-intensity interval training (HIIT) has shown promise in some PCOS studies for improving insulin sensitivity, though the evidence base is still developing and it may not suit everyone, particularly those new to exercise or with joint concerns.

Resistance training, using weights, resistance bands, or bodyweight exercises, builds lean muscle mass, which increases the body's resting metabolic rate and improves glucose uptake by muscle cells. Combining aerobic and resistance training appears to offer greater metabolic benefit than either approach alone. Even modest increases in activity, such as replacing a short car journey with a walk, can contribute meaningfully over time.

Very intense exercise programmes without adequate recovery may not be appropriate for everyone, and a balanced, sustainable routine is generally more beneficial than an extreme short-term effort. If you are unsure where to start, a GP or physiotherapist can advise on a suitable programme.

Can medication help with PCOS-related weight around the stomach?

Metformin is the most commonly used medicine for PCOS-related abdominal fat, improving insulin sensitivity; GLP-1 receptor agonists such as semaglutide and tirzepatide may also be considered where obesity criteria are met.

Medication can play a supportive role in managing PCOS-related abdominal fat, particularly when lifestyle changes alone have not produced sufficient improvement. The most commonly used medicine in this context is metformin, which is not licensed specifically for weight loss but is used in PCOS to improve insulin sensitivity. NICE CKS on PCOS recommends that metformin be considered for people with PCOS who have a BMI above 25 kg/m2 and metabolic features such as impaired glucose tolerance.^[1][19] It works by reducing hepatic glucose production and improving cellular response to insulin, which can indirectly support weight management and reduce central adiposity over time. Metformin use in PCOS is off-label; long-term use is also associated with a risk of vitamin B12 deficiency, which the BNF recommends monitoring for.^[2][3]

For people with PCOS who also meet the criteria for obesity-related treatment, GLP-1 receptor agonists represent a newer option. Semaglutide (available as Wegovy, licensed for chronic weight management, or Ozempic, which is licensed for type 2 diabetes only) and tirzepatide (Mounjaro, licensed in the UK for both type 2 diabetes and chronic weight management) act on appetite-regulating pathways in the brain, slow gastric emptying, and improve insulin sensitivity.^[5][6] Clinical trials have demonstrated meaningful reductions in body weight and waist circumference with these medicines, though they are prescribed within specific eligibility criteria and are not a standalone solution without lifestyle support.

Important safety information for GLP-1 receptor agonists: the SmPCs for both semaglutide and tirzepatide advise that these medicines should not be used during pregnancy or whilst breastfeeding. People who could become pregnant should use effective contraception during treatment. The Mounjaro UK SmPC additionally advises using a non-oral contraceptive method for four weeks after starting treatment and for four weeks after each dose increase, as the medicine may reduce the effectiveness of oral contraceptives. These medicines should be stopped before a planned pregnancy; discuss timing with your prescriber.

Common side effects of GLP-1 receptor agonists include nausea, vomiting, and diarrhoea, particularly when starting treatment or increasing the dose. Metformin can also cause gastrointestinal side effects, which are usually reduced by taking it with food.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of treatment options may be considered if clinically appropriate.

Any medication for PCOS should be discussed with a GP or specialist, who can assess suitability and monitor for side effects. Suspected adverse effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

How long does it take to see results when managing PCOS belly fat?

Measurable reductions in waist circumference typically occur after 12 to 24 weeks of consistent lifestyle change; a 5 to 10 per cent reduction in body weight can produce clinically significant hormonal and metabolic improvements.

Meaningful reductions in PCOS-related belly fat typically take several months of consistent effort, and the timeline varies considerably depending on the individual's degree of insulin resistance, hormonal profile, starting weight, and the combination of strategies being used. Clinical studies in PCOS generally report measurable improvements in waist circumference and metabolic markers after around 12 to 24 weeks of sustained dietary and exercise changes, though some people notice improvements in energy, mood, and bloating within the first few weeks, even before significant fat loss is visible.^[15][16]

It is important to set realistic expectations. PCOS-related abdominal fat is driven by hormonal and metabolic factors that do not resolve quickly, and the body's response to lifestyle change may be slower than in people without the condition. Research, including the 2023 International Evidence-Based Guideline for PCOS, indicates that a weight loss of 5 to 10 per cent of body weight can produce clinically significant improvements in insulin resistance, androgen levels, and menstrual regularity in people with PCOS, even when the absolute amount of weight lost appears modest.^[11]

Progress is best tracked using a combination of measures rather than the scales alone. Waist circumference and how clothes fit can reflect meaningful change. In UK primary care, glycaemic status is typically assessed using HbA1c or an oral glucose tolerance test (OGTT) rather than fasting insulin, and your GP can advise on which tests are appropriate for you.

If there has been no meaningful progress after three to six months of consistent lifestyle change, it is reasonable to return to a GP to discuss whether additional investigation or medical support is appropriate. Conditions such as hypothyroidism or obstructive sleep apnoea, which can co-exist with PCOS and impair weight management, should be excluded if not already assessed.

Seek prompt medical advice if you experience rapidly worsening symptoms such as significant new hair growth or hair loss, very heavy or irregular bleeding, or other features that concern you, as these may warrant specialist review.

Scientific References

1. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6) — full document.
2. Metformin hydrochloride | Drugs — BNF — NICE.
3. Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk.
4. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
5. Semaglutide | Drugs — BNF — NICE.
6. Semaglutide: a medicine to manage type 2 diabetes or obesity — NHS.
7. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
8. Tirzepatide | Drugs — BNF — NICE.
9. Physical activity guidelines: UK Chief Medical Officers' report.
10. Physical activity guidelines for adults aged 19 to 64 — NHS.
11. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (ESHRE/ASRM).
12. Abdominal adiposity and the polycystic ovary syndrome. Escobar-Morreale HF et al. 2007.
13. The potential role of the Mediterranean diet for polycystic ovary syndrome. Scannell N et al. 2025.
14. Nutrition interventions in women with polycystic ovary syndrome: a systematic review. European Journal of Nutrition.
15. Lifestyle interventions for cardiometabolic health in women with polycystic ovary syndrome: a systematic review and network meta-analysis. Human Reproduction Update.
16. Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Physiology.
17. Adipose-androgen crosstalk in polycystic ovary syndrome: mechanisms and therapeutic implications. Frontiers in Endocrinology.
18. Neuroendocrine regulation of adipose partitioning in polyendocrine metabolic ovarian syndrome: the gut-brain-adipose axis. Journal of Endocrinological Investigation.
19. Polycystic ovary syndrome: metformin in women not planning pregnancy — information for the public (ESUOM6).

Frequently Asked Questions